The Point Tile

The Point Blog ARCHIVE
All articles found in the archive are more than three years old.


The purpose of this blog is to stimulate thought and discussion about important issues in healthcare. Opinions expressed are those of the author and do not necessarily express the views of CMDA. We encourage you to join the conversation on our website and share your experience, insight and expertise. CMDA has a rigorous and representative process in formulating official positions, which are largely limited to bioethical areas.

Artificial Wombs and Modern Incubators

May 11, 2017

by David Prentice, PhD

Sometimes what seems like science fiction can actually be science fact, and sometimes new technologies can have the potential for both good and bad uses. So-called “dual-use technology” is most often thought of in connection with potential military as well as civilian use, e.g., weaponized forms of viruses or bacteria vs. using such altered pathogens for vaccine development. At other times, the dual use may turn on bioethical evaluations of the use of technology, especially as it relates to use with human beings. The recently-developed artificial womb may be one such possibility. Scientists at Children’s Hospital of Philadelphia published their work on development of an artificial womb, testing the functionality with pre-term lambs. The simple design, utilizing a biobag as the sterile enclosure, coupled with several advances in linking circulatory system and facilitating oxygenation, give this new artificial womb the potential for successful gestation of pre-term infants (the full publication is available at Nature Communications.) This artificial womb is designed to give extremely pre-term infants the chance for a bit more development, especially for lung maturation, in a fluid-bathed environment similar to the normal womb, before they enter the air-filled world. In this sense, this artificial womb is really an innovative incubator.

Current treatment of extremely pre-term infants involves an incubator and intubation, along with stimulants for lung maturation, but the mechanical breathing apparatuses can often do more damage than good for the highly fragile lungs of such tiny infants. The fluid-filled bags in which the lambs were incubated provide an environment similar to the native womb, with fluid filling the lungs, and rather than a mechanical pump for circulation, which can cause significant damage to tissues, the fetal heart itself acts to pump the tiny volume of fluid to bring oxygenated blood to the lamb. Another innovation is a well-designed interface with the end of the umbilical cord, providing a snug fit and greatly reduced chance of hemorrhage, compared to insertion of needles into umbilical vein and artery.

Extremely premature babies at 20, 21 and 22 weeks after fertilization (22, 23 and 24 weeks gestational age) are now surviving outside the womb when given medical interventions, and the interventions and attitudes regarding intervention now indicate as many as 61 percent of these extremely pre-term infants may survive, including 25 percent without severe complications. But given further care and opportunity to develop and especially for lung maturation, it is likely many more would survive, and without complications.

This new artificial womb is definitely not akin to the laboratory “hatcheries” depicted in Aldous Huxley’s Brave New World. A year ago, we discussed the science that is pushing the envelope at the beginning of human life, growing human embryos in vitro for longer periods and even past the normal point of implantation into the uterine lining. Some are attempting to develop artificial wombs to supplant the normal womb for this early stage of development. Such designs do cross an ethical line, not only in terms of the instrumental use and destruction of human embryos inherent in such experiments, but also by virtue of the attitude this shows toward human life and normal human development. Such laboratory constructs for human embryo development are certainly no substitute for a mother’s womb; there are a great many fetal-maternal interactions very early and throughout development that we do not as yet understand, both in terms of biology as well as psycho-social connections.

Could this new, innovative incubator (the artificial womb for pre-term infants) also change the view around “viability,” both in medical and legal frameworks? It is potentially possible for this artificial womb to be put into service for infants even earlier in development. The aim of this innovative artificial womb is support for extremely pre-term babies, to give them a better chance for survival. In that respect, the real issue is keeping in focus the humanity and care of this tiniest of patients.

David Prentice, PhD

David Prentice, PhD

David A. Prentice is Vice President and Research Director for the Charlotte Lozier Institute. He is also Adjunct Professor of Molecular Genetics at the John Paul II Institute, The Catholic University of America and was a Founding Advisory Board Member for the Midwest Stem Cell Therapy Center, a unique comprehensive stem cell center in Kansas that he was instrumental in creating. In 2020, he was appointed by the Secretary of HHS to the federal Human Fetal Tissue Ethics Advisory Board. Dr. Prentice has over 40 years’ experience as a scientific researcher and professor, including previous service as senior fellow for life sciences at the Family Research Council, Professor of Life Sciences at Indiana State University, and Adjunct Professor of Medical and Molecular Genetics, Indiana University School of Medicine.

He established Stem Cell Research Facts, an educational website providing scientific facts and patient-centered videos about adult stem cells, and is a founding member of Do No Harm: The Coalition of Americans for Research Ethics, and an advisory board member for the Center for Bioethics and Human Dignity. He has provided scientific advice for numerous medical professionals, legislators, policymakers and organizations at the state, federal, and international levels.

Dr. Prentice received his Ph.D. in biochemistry from the University of Kansas, and was at Los Alamos National Laboratory and the University of Texas Medical School-Houston before joining Indiana State University where in addition to his research and teaching, he served as Acting Associate Dean of Arts and Sciences and Assistant Chair of Life Sciences. He was recognized with the University’s Caleb Mills Distinguished Teaching Award and Faculty Distinguished Service Award. He has taught courses ranging from non-majors biology to advanced and graduate courses including developmental biology, embryology, cell and tissue culture, history of biology, science and politics, pathophysiology, medical genetics, and medical biochemistry. Several of his courses were also taught on-line.

He received the 2007 Walter C. Randall Award in Biomedical Ethics from the American Physiological Society, given for promoting the honor and integrity of biomedical science through example and mentoring in the classroom and laboratory. Dr. Prentice’s research interests encompass various aspects of cell growth control, cell and developmental biology; one major focus is adult stem cells. He has reviewed for various professional publications including The Journal of the American Medical Association.

He is an internationally-recognized expert on stem cell research, cell biology and bioethics, and has provided scientific lectures and policy briefings in 40 states and 21 countries, including testimony before the U.S. Congress and numerous state legislatures, the U.S. National Academy of Sciences, the President’s Council on Bioethics, European Parliament, British Parliament, Canadian Parliament, Australian Parliament, German Bundestag, French Senate, Swedish Parliament, the United Nations, and the Vatican. He was selected by President George W. Bush’s U.S. President’s Council on Bioethics to write the comprehensive review of adult stem cell research for the Council’s 2004 publication “Monitoring Stem Cell Research.”

Dr. Prentice has published numerous scientific and bioethics articles, including a recent review of stem cell science and adult stem cell treatments published in Circulation Research. He has also published numerous commentaries and op-eds, and travels nationally and internationally to give frequent invited lectures regarding stem cell research, fetal tissue research, gene editing, cloning, embryology, cell culture and vaccines, bioethics, and public policy. He has been interviewed in virtually all major electronic and print media outlets, including CNN, ABC, NBC, CBS, Fox, CSPAN, Reuters, AP, NPR, USA Today, BBC, The Washington Post, The Los Angeles Times, and The New York Times.